Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Short term Debt (2017 - 2023)

Capricor Therapeutics has reported Short term Debt over the past 7 years, most recently at $18628.0 for Q2 2023.

  • Quarterly results put Short term Debt at $18628.0 for Q2 2023, down 80.21% from a year ago — trailing twelve months through Jun 2023 was $18628.0 (down 80.21% YoY), and the annual figure for FY2022 was $89234.0, down 85.11%.
  • Short term Debt for Q2 2023 was $18628.0 at Capricor Therapeutics, roughly flat from $18716.0 in the prior quarter.
  • Over the last five years, Short term Debt for CAPR hit a ceiling of $599388.0 in Q4 2021 and a floor of $18628.0 in Q2 2023.
  • Median Short term Debt over the past 3 years was $89234.0 (2022), compared with a mean of $211300.7.
  • Peak annual rise in Short term Debt hit 80.21% in 2023, while the deepest fall reached 96.74% in 2023.
  • Capricor Therapeutics' Short term Debt stood at $599388.0 in 2021, then crashed by 85.11% to $89234.0 in 2022, then tumbled by 79.12% to $18628.0 in 2023.
  • The last three reported values for Short term Debt were $18628.0 (Q2 2023), $18716.0 (Q1 2023), and $89234.0 (Q4 2022) per Business Quant data.